The available intravenous iron formulations: History, efficacy, and toxicology

Hemodialysis International

Volumn 21, Issue , 2017, Pages S83-S92

  Auerbach, Michael ^a,b   Macdougall, Iain ^c  

^a Auerbach Hematology and Oncology   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

chronic kidney disease; Intravenous iron; iron deficiency anemia

Indexed keywords

DEXTRAN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON SACCHARATE; FERRIC ION; MAGNETITE; MALTOSE;

CHEMOTHERAPY INDUCED ANEMIA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; END STAGE RENAL DISEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODIALYSIS; HUMAN; HYPERSENSITIVITY; IRON DEFICIENCY; REVIEW; ANALOGS AND DERIVATIVES; ANEMIA; CHRONIC KIDNEY FAILURE; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION;

ANEMIA; DRUG COMPOUNDING; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALTOSE; RENAL DIALYSIS;

EID: 85016545137     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12560     Document Type: Review

References (55)

1. Macdougall I, Vernon K. Complement activation-related pseudo-allergy: A fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017; 45:60–62.
2. Hempel J, Poppelaars F, Gaya de Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017; 45:45–59.
3. Goetsch A, Moore C, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hyperchromic anemia. Blood. 1946; 1:129–142.
4. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol. 2008; 83:580–588.
5. Baird I, Padmore D. Intra-muscular iron therapy in iron deficiency anemia. Lancet. 1954; 2:942.
6. Marchasin S, Wallerstein R. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood. 1964; 23:354–358.
7. Hamstra R, Block M, Schocket A. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243:1726–1731.
8. Chertow G, Mason P, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004; 19:1571–1575.
9. Wang C, Graham D, Kane R, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015; 314:2062–2068.
10. DeLoughery T, Auerbach M. Is low-molecular weight iron dextran really the most risky iron?—Unconvincing data from an unconvincing study. Am J Hematol. 2016; 91:452–452.
11. Auerbach M, DeLoughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematol Am Soc Hematol Educ Program. 2010; 2010:338–347.
12. Auerbach M, Pappadakis J, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011; 86:860–862.
13. Schrier S, Auerbach M. Treatment of anemia due to iron deficiency. In: Tirnaer J, ed. Wolters Kluwer, 2016.
14. Wong L, Smith S, Gilstrop M, et al. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. Am J Hematol. 2016; 91:590–593.
15. Ayub R, Tariq N, Adil M, et al. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008; 18:424–427.
16. Auerbach M, Smith S, James S. Results of the first American prospective study of IV iron in oral iron intolerant iron deficient gravidas. Presented at the 2016 annual meeting of the American Society of Hematology. Blood. 2016; 128. Abstract #1277.
17. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc. 2015; 90:12–23.
18. Michael B, Coyne D, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002; 61:1830–1839.
19. Coyne D, Adkinson N, Nissenson A, et al. Sodium ferric gluconate complex in hemodialysis patients II. Adverse events in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003; 63:217–224.
20. Chandler G, Harchowal J, Macdougall I. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis. 2001; 38:988–991.
21. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999; 33:464–470.
22. Michael B, Coyne D, Folkert V, et al. Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant. 2004; 19:1576–1580.
23. Henry D, Dahl N, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12:231–242.
24. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26:1619–1625.
25. Silverberg D, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients no receiving dialysis. Am J Kidney Dis. 1996; 27:234–238.
26. Mircescu G, Garneata L, Capusa C, et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006; 21:120–124.
27. Agarwal R, Kusek J, Pappas M. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015; 88:905–914.
28. Macdougall I, Bock A, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymatlose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol Dial Transplant. 2014; 29:717–720.
29. Gasche C, Lomer M, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004; 53:1190–1197.
30. Kochar P, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: A randomized clinical trial. J Obstet Gynaecol Res. 2013; 39:504–510.
31. Bastit L, Vandbroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with and without intravenous iron in patients with chemotherapy induced anemia. J Clin Oncol. 2008; 26:1611–1618.
32. Cuenca J, Garcia-Erce J, Martinez A, et al. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair. Preliminary data. Arch Orthop Trauma Surg. 2005; 125:342–347.
33. Malone M. Recommended nutritional supplements for bariatric surgery patients. Ann Pharmacother. 2008; 42:1851–1858.
34. Krayenbuehl P, Battegay E, Breymann, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenapausal women with low serum ferritin concentration. Blood. 2011; 118:3222–3227.
35. Jahn M, Andreasen H, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78:480–491.
36. Sav T, Tokgoz B, Sipahioglu M, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail. 2007; 29:423–426.
37. Moniem K, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Alternat Transfus Med. 2007; 9:37–42.
38. Critchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose): A systematic review. Transfus Alternat Transfus Med. 2007; 9:8–36.
39. Okam M, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012; 87:E123–E124.
40. Balakrishnan V, Rao M, Kausz A, et al. Physiochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009; 39:489–496.
41. Spinowitz B, Kausz A, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19:1599–1605.
42. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patietns. Clin J Am Soc Nephrol. 2009; 4:386–393.
43. Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther. 2014; 36:70–83.
44. Macdougall I, Strauss W, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2004; 9:705–712.
45. Macdougall I, Dahl N, Bernard K, et al. The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: Background and rationale. BMC Nephrol. 2017; 18:24–26.
46. Roger S, Gaillard C, Bock A, et al. Safety of intravenous ferric carboxymaltose versus oral ironin patient with nondialysis dependent CKD: An analysis of the 1-year FIND-CKD trial. Nephrol Dial Transplant. 2017, doi:doi.org/10/1093/ndt/gfw264.
47. Anker S, Comin C, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361:2436–2448.
48. Ponikowski P, van Verdhuisen D, Comin C, et al. Beneficial effects of long term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015; 36:657–668.
49. Wolf M, Koch T, Bregman D. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013; 28:1793–1803.
50. Estatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141:846–853.
51. Steinmetz T, Tscechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anemia. Ann Oncol. 2013; 24:475–482.
52. Derman R, Roman E, Modiano M, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017; 3:286–291.
53. Kalra P, Bhandar S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent-chronic kidney disease patients with anemia. Nephrol Dial Transplant. 2016; 31:646–655.
54. Bhandari S, Kalra S, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in hemodialysis patients. Nephrol Dial Transplant. 2015; 30:1577–1589.
55. Danielson B. Structure, chemistry and pharmacokinetics of intravenous iron agent. J Am Soc Nephrol. 2004; 15:S93–S98.